[Diabetes insipidus--various recent aspects].
D000818:Animals; D001120:Arginine / Q000096:biosynthesis; D002220:Carbamazepine / Q000009:adverse effects; D002747:Chlorpropamide / Q000009:adverse effects; D002994:Clofibrate / Q000009:adverse effects; D000242:Cyclic AMP / Q000096:biosynthesis; D003919:Diabetes Insipidus / Q000139:chemically induced / Q000209:etiology / Q000235:genetics / Q000378:metabolism / Q000662:veterinary; D007031:Hypothalamus / Q000503:physiopathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000150:complications; D008094:Lithium / Q000009:adverse effects; D008733:Methoxyflurane / Q000009:adverse effects; D010452:Peptide Biosynthesis; D014176:Protein Biosynthesis; D051381:Rats; D012376:Rodent Diseases / Q000235:genetics; D013752:Tetracycline / Q000009:adverse effects; D014667:Vasopressins / Q000096:biosynthesis; D014707:Vermont
D014667:Vasopressins; D008733:Methoxyflurane; D002220:Carbamazepine; D001120:Arginine; D008094:Lithium; D000242:Cyclic AMP; D013752:Tetracycline; D002994:Clofibrate; D002747:Chlorpropamide
Diabète insipide--quelques aspects récents